Raloxifene: Is it really effective on mood changes in postmenopausal osteopenic women?

Journal of Psychosomatic Obstetrics and Gynecology

Volumn 31, Issue 4, 2010, Pages 273-278

  Karageyim Karsidag, A Yasemin ^a   Karsidag, Cagatay ^b   Buyukbayrak, Esra Esim ^a   Kars, Bulent ^a   Pirimoglu, Meltem ^a   Unal, Orhan ^a   Turan, M Cem ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Department of Psychiatry Clinic   (Turkey)

Author keywords

anxiety; Depression; menopause; raloxifene

Indexed keywords

CALCIUM; PLACEBO; RALOXIFENE;

ADULT; ANXIETY; ARTICLE; BECK ANXIETY RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; KUPPERMAN SCALE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MOOD CHANGE; OSTEOPENIA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UNSPECIFIED SIDE EFFECT;

ADULT; AFFECTIVE SYMPTOMS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM, DIETARY; EMOTIONS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78249283256     PISSN: 0167482X     EISSN: 17438942     Source Type: Journal    
DOI: 10.3109/0167482X.2010.524718     Document Type: Article

References (22)

1. Harlow BL, Cohen LS, Otto MW, Spiegelman D, Cramer DW. Prevalence and predictors of depressive symptoms in olderpremenopausal women: the Harvard study ofmoods and cycles. Arch Gen Psychiatry 1999;56:418-424.
2. Inan I, Kelekci S, Yilmaz B. Psychological effects oftibolone and sequential estrogenprogestogen therapy in perimenopau-sal women. Gynecol Endocrinol 2005;20:64-67.
3. Huttner RP, Shepherd JE. Gonadal steroids, selective serotonin reuptake inhibitors, and mood disorders in women. Med Clin NortAm 2003;87:1065-1076.
4. Yen SSC, Jaffe RB. Reproductive endocrinology. Philadelpia: W.B. Sonders; 1991.
5. Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynaecol 1996;87:20-26.
6. Baksu A, Ayas B, Citak S, Kalan A, Baksu B, Goker N. Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical meno-pause. Int J Gynaecol Obstet 2005;91:58-62.
7. Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan S, Elman S, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002;63(Suppl. 7):45-48.
8. Khovidhunkit W, Shoback DM. Clinical effects ofraloxifene hydrochloride in women. Ann Intern Med 1999;130:431-439.
9. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
10. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
11. Cyr M, Landry M, Di Paolo T. Modulation by estrogenre-ceptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000;23:69-78.
12. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook III TH. Raloxifene hydrochloride, a selective estrogen receptor mod-ulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999;24:115-128.
13. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality oflife in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000;96:359-365.
14. Kupperman HS, Blat MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13:688-703.
15. Bekiroglu N, Gurbuz A, Konyalioglu R, Ayas S, Akif A, Eren S. The comparison of menopause rating scale (MRS), Kupperman index (KI) and Nottingham health profile (NHP) by means of reliability measures and responsiveness indexes among menopausal women. Zeynep Kamil Tip Bülteni 2008;39:11-16.
16. Bech P, Hamilton M, Zung WWK. The Bech, Hamilton and Zung scales for mood disorders: screening and listening: A twenty years update with reference to DSM-IV and ICD-10. 2nd ed. Berlin: Springer-Verlag; 1996.
17. Akdemir A, Orsel S, Dag I, Turkcapar H, Iscan N, Ozbay H. The validity, reliability and clinical use of Hamilton depression rating scale. J Psychiatr Psychol Psychopharmacol 1996;4: 251-259.
18. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897.
19. Ulusoy M, Sahin N, Erkman H. Turkish Version ofthe Beck Anxiety Inventory: psychometric properties. J Cognit Psy-chotherapy: Int Quaterly 1988;12:28-35.
20. Jarkova NB, Martenyi F, Masanauskaite D, Walls EL, Smetnik VP, Pavo I. Mood effect of raloxifene in postmeno-pausal women. Maturitas 2002;42:71-75.
21. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine en-dometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
22. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.